Xortx Therapeutics Inc. Stock
Price
Target price
€0.77
€0.77
-4.130%
-0.032
-4.130%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Xortx Therapeutics Inc. Stock
Heavy losses for Xortx Therapeutics Inc. today as the stock fell by -€0.032 (-4.130%).
For the coming years our community has positive and negative things to say abot the Xortx Therapeutics Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Xortx Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
XORTX Announces USD $3 Million Offering
- Proceeds will be used to advance XORTX’s programs for gout -
CALGARY, AB – May 19, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
XORTX Provides Update on FDA Type B Meeting Request
XORTX will focus on key steps to advance a NDA filing for Gout indication
CALGARY, AB – April 30, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX |
XORTX Announces Grant of European Patent
- Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease Programs -
CALGARY, AB – April 28, 2025 – XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX |